Tessa Therapeutics, a therapy firm based in Singapore has raised $126 million in its Series A round to support the development of immune cell therapies for cancer.
- The funds will help the firm to scale its cancer therapy development including the clinical trial of the TT11 programme and TT11x programme.
- Founded in 2012, Tessa is a biotechnology firm focusing on CAR-T therapy, the harvesting of the immune cells in a patient, engineered to focus on cancer cells and infused in the patient.
- The firm has a recorded around 57% complete response or disappearance of cancer cells in its TT11 ongoing phase 2 trial and complete disappearance of tumours in 4 out 9 cancer patients in its TT11x phase 1 study.
- Polaris Partners led the funding round with participation from Temasek, EDBI, Heliconia Capital, and Heritas Capital.